Throw! Innovation "snatching" game opens! Several MNCs have entered the game with pitching.

AstraZenecom's first global industrial investment fund has been moving this year as a multinational pharmaceutical industry fund that has re-invested in China's innovative healthcare industry, following Lilly Asia Ventures(LAV).
bi and Sanofi have joined the wave of innovation in China's pharmaceutical industry through indirect methods this year.
also means that in the eyes of these multinational pharmaceutical companies, the time is ripe to share the dividends of China's pharmaceutical innovation and development.
the first half of 2020, 484 new drugs were clinically debuted, with an average of 3.75 days in July.
way to avoid missing out on the next 10 years of Chinese pharmaceutical innovation is to find ways to grow with them.
,01 AstraZeneone's $1 billion fund, which has had double-digit positive growth in China in the first half of the year, has come together with Fish Leap Healthcare.
AstraZeneta's domestic circle of friends has once again strengthened.
evening of The 9th, Fish Leap Medical announced that the company with its own capital of 200 million yuan, to participate in the investment in the establishment of AstraZeneta China Capital Venture Capital Partnership (limited partnership) (tentative name of the enterprise).
the partnership is limited to 7 years and the partnership may not exceed $2.5 billion.
announcement shows that the purpose of the partnership is very clear, that is, mainly in China's medical and health industry-related unlisted enterprises equity or listed enterprises to invest in activities.
This is not the first time AstraZeneca has established such a strong relationship with a domestic company, and at the end of August Tyger Pharmaceuticals announced that it intended to invest 50 million yuan in the AstraZeneca-CICC fund, together with AstraZeneca and CIC Capital.
AstraZeneca, which is transforming from a traditional pharmaceutical company to an innovative platform company, is starting to join the wave of innovative pharmaceutical companies in China in a lighter and faster way, unlike its previous industrial base and global hub.
AstraZeneta's ambitions are no longer limited to pharmaceutical companies, but to an all-ecological layout.
At AstraZeneta's China Ecosphere Conference this year, Its Global Executive Vice President, International Business and China President Wang Lei said AstraZene commerce looks forward to further in-depth cooperation with partners in the pharmaceutical, device, digital, diagnostic, capital and other fields to explore the application of cutting-edge technologies and innovative business models in the medical field and promote AstraZeneta's innovation strategy across the country.
support for this strategic layout is the Global Industry Fund.
2019, AstraZeneta announced the joint establishment of a global healthcare industry fund with COFCOM Capital in Wuxi.
fund is AstraZeneta's first and largest healthcare industry fund raised globally and the first to be grafted in China by AstraZeneta, with an expected funding target of $1bn.
's importance to the fund, as AstraZeneta has stated, is an important milestone in AstraZeneta's global innovation strategy.
The fund focuses on the entire industrial chain, including global new drug research and development, production operations and commercial development, providing all-round support to innovative enterprises at home and abroad, accelerating the optimization and integration of China's medical resources, expanding the introduction of overseas innovation and local innovation incubation, and promoting China's innovation to benefit the world.
understood that such corporate investment funds can quickly help parent companies get new information and ideas from outside, helping them return to the forefront of innovation.
, which launches such funds, often plays an important role in supporting the export industry chain and also helps invested companies to complete the difficult growth process from 0 to 1.
, lilies, another multinational drug company, did the same long before AstraZeneta set up its corporate venture capital fund.
the fund began in 2008 in Lilly Pharmaceuticals' venture capital division and became an independent investment management company in 2011, according to Lilly's Official Website.
manages a total of more than $1.2 billion in assets, including five U.S. dollar funds, including Lilly Asia Ventures Fund I, and four RMB funds, including the Lillian Fund.
The fund's parent company, Lilly Pharmaceuticals, was once a global TOP10 multinational, but lilly's sales fell to 14th place in the world in 2019 on the top 50 list of global pharmaceutical companies in 2020, according to the American Journal of Pharmaceutical Managers.
the fund's parent company, the Global Top 10, Lilly's Asian fund has reaped a lot in the Chinese market.
understand that Lilly Asia Fund has invested in more than 110 companies around the world, and its official website shows 58 portfolio companies.
including a number of China's medical sector star enterprises, such as micro-core biology, Thyda, Beda Pharmaceuticals, Concino, Sansheng Pharmaceuticals, stone-burning medicine, Sanxiang Biology and so on. according to
's public reports, Lilly Asia Fund has had eight capital incidents this year, and its leading projects include a $100 million round A financing of Dizhe Pharmaceuticals, a $30 million round E financing of Nohui Health, a 170 million yuan round of financing for Guangzhou-based Peng Pharmaceuticals, and a $100 million financing for Rongchang Bio.
involved in the investment projects include a $115 million C round of financing for Cornell Biopharmaceuticals, a $70 million C round of financing for Yuyu Pharmaceuticals, and a $100 million B-plus round of financing for Genesis Group.
also strategically invested $150 million in Legendary Bio.
on September 30th Garcos, the company in which Lilly Asia fund will invest in 2017, filed an IPO application with the Stock Exchange of Hong Kong under Chapter 18A, which is about to become another listed company backed by the fund.
's Asia Fund is a pioneer in investing in innovative chinese medicines.
the global financial crisis in 2009, Lilly Asia began looking for and investing in leading products and companies in the Chinese market 5-10 years later.
fund focuses on Chinese companies in biopharmaceuticals, medical technology, medical devices and diagnostics, with 70% of its investments in China and continues to invest in them from seed stage until the open market after the IPO.
Innovating pharmaceutical enterprises research and development risk is high, long cycle, "burning money" fast, Lilly Asia Fund for the choice of investment targets, first of all, to see whether its team is excellent, whether there is a continuous creation of potential product pipeline, and this also means that enterprises have the quality to resolve the risk.
to examine the project, it pays great attention to its available data to determine whether they can provide strong support and support for the next phase of the study.
Lilly Asia Fund focuses on areas where market demand is not being met, and for its bullish track and target, Lilly Asia Fund will provide a lot of value-added services and support to the end, in addition to continuing to invest in companies, based on the resources and industry chain advantages of its parent company.
, for example, Cynda Bio was established in 2011 and Lilly Asia Fund led its Round A financing in 2012.
And the fund has led to more than $2 billion in partnerships between Cynda Bio and Lilly Pharmaceuticals of the United States, at one point creating the largest partnership between China's biopharmaceutical companies and multinational pharmaceutical companies at the time, helping Cynda reduce the risk of operational research and development and greatly boosting Cynda's growth.
addition, Lilly Asia Fund continued to provide blood transfusions to Cymdeit, participating in the $100 million financing of Cymeda BioC in 2015 and $150 million in round E in 2018.
02 Sanofi, BI have thrown an olive branch, like AstraZeneta and Lilly, and those who don't want to miss out on the development dividends of China's innovative pharmaceutical companies are Sanofi and Grigg Ingham (BI).
but unlike AstraZeneta and Lilly, which set up venture capital funds, the two practices are more "euphemistic".
, Sanofi announced a strategic investment in the global venture capital fund Kaihui Innovation Fund.
, Sanofi hopes to use the advantages of Kaihui's selection and investment companies to help Sanofi connect with Chinese healthcare start-ups.
China is Sanofi's second largest market in the world and one of Sanofi's global strategic priorities. Olivier Charmeil, executive vice president of
Sanofi and head of Pharm's global division, said, "China's market dynamics and rapid breakthroughs in digital innovation are impressive and demonstrate its potential to be a global leader in the digital economy."
" and Sanofi's strategic partnership will enable it to accelerate the distribution of innovations in medical technology and ultimately translate them into tangible benefits.
25th anniversary of its entry into China, bi has also begun to lay out innovation in all aspects of China.
On the one hand, BI plans to increase its capital to China by 451 million euros over the next five years, and this year announced the establishment of BI X, a digital innovation laboratory in Shanghai, to launch and implement the China Key project, becoming the first multinational pharmaceutical company to fully integrate China into early-stage clinical development projects around the world.
, in July, BI launched the China External Innovation Cooperation Center as one of the company's strategic pillars.
The center will provide innovators in the biopharmaceutical industry in China and Asia with one-stop, innovative solutions, from early research and innovation collaboration to strategic investment, with a process that helps them realize innovative ideas.
Zhang Yiyi, director of the
Center, believes that the whole of Asia is becoming a hot spot for biomedical research, with China's biomedical innovation capabilities significantly increasing and BI's goal being to be the preferred partner in the innovation ecosystem.
best time to plant a tree was ten years ago, followed by now.
, a partner at Lilly Asia, has said that this is the best time for innovation in China's pharmaceutical sector.
for multinational pharmaceutical companies, if you miss the golden age of China's innovative pharmaceutical companies' initial development, then don't miss the 2.0 era of competition for new drugs in China.
a decade ago, if China's innovative pharmaceutical companies were short of talent and the state's policy of supporting innovation was unclear, it is not what it used to be.
the first half of 2020, 484 new drugs were clinically announced for the first time.
the end of August, the number of listed pharmaceutical/medical companies in China reached a new high, with more than 40 listings, which are expected to surpass the 2017 peak of 50.
drug review and approval has been speeding up, Rongchang Bio's injection with wedixito monoanti and cornerstone pharmaceutical industry Platini capsules used less than a week to be proposed priority review publicity.
on the global stage, the number of clinical trials conducted in China in the first half of 2020 exceeded that of the United States, with 251 biosypolybic drugs leading the world... At the same time, China is increasingly concerned about investment institutions in the pharmaceutical sector.
also have several corporate investment funds similar to AstraZeneta and Lilly's Asian funds.
, for example, China National Pharmaceutical Group launched in 2012 to set up a three-phase fund, a total of more than 6 billion yuan worth of management funds.
Pharmaceutical Mingkang is mainly through the establishment of investment management companies (such as Shanghai Pharmaceutical Mingkang Investment Management Co., Ltd.) and participate in equity investment funds (such as Mint Angels, Tong and Cheng's funds) to carry out holding, minority equity out-of-country investment.
And Huada Gene through the establishment of fund management companies (such as Shenzhen Huada Gene Industry Investment Fund Management Co., Ltd.), Fosun Pharma mainly through Fosun Pingyao, rehabilitation equity and other investment institutions to carry out minority equity out-investing ...